Trehalose does not improve neuronal survival on exposure to alpha-synuclein pre-formed fibrils

Redox Biology

Volumn 11, Issue , 2017, Pages 429-437

  Redmann, Matthew ^a,b   Wani, Willayat Y ^a,b   Volpicelli Daley, Laura ^b,c   Darley Usmar, Victor ^a,b   Zhang, Jianhua ^a,b,c,d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Alpha synuclein fibrils; Autophagy; LC3 II; P alpha synuclein trehalose; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CELL PROTEIN; PS129 PROTEIN; TREHALOSE; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BRAIN CORTEX; BRAIN NERVE CELL; CELL DEATH; CELL INCLUSION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STRUCTURE; ANIMAL; APOPTOSIS; GENETICS; HUMAN; METABOLISM; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; PROTEINOSIS;

ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; AUTOPHAGY; CELL SURVIVAL; HUMANS; MICE; NEURONS; PARKINSON DISEASE; PROTEIN AGGREGATION, PATHOLOGICAL; TOR SERINE-THREONINE KINASES; TREHALOSE;

EID: 85008343617     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2016.12.032     Document Type: Article

References (34)

1. [1] Damier, P., Hirsch, E.C., Agid, Y., Graybiel, A.M., The substantia nigra of the human brain. II. patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain: J. Neurol. 122 (1999), 1437–1448.
2. [2] Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., Alpha-synuclein in Lewy bodies. Nature 388:6645 (1997), 839–840.
3. [3] Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q., Iwatsubo, T., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152:4 (1998), 879–884.
4. [4] Spillantini, M.G., Crowther, R.A., Jakes, R., Cairns, N.J., Lantos, P.L., Goedert, M., Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251:3 (1998), 205–208.
5. [5] Lee, H.J., Cho, E.D., Lee, K.W., Kim, J.H., Cho, S.G., Lee, S.J., Autophagic failure promotes the exocytosis and intercellular transfer of alpha-synuclein. Exp. Mol. Med., 45, 2013, e22.
6. [6] Volpicelli-Daley, L.A., Luk, K.C., Patel, T.P., Tanik, S.A., Riddle, D.M., Stieber, A., Meaney, D.F., Trojanowski, J.Q., Lee, V.M., Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:1 (2011), 57–71.
7. [7] Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J.Q., Lee, V.M., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:6109 (2012), 949–953.
8. [8] Cuervo, A.M., Bergamini, E., Brunk, U.T., Droge, W., Ffrench, M., Terman, A., Autophagy and aging: the importance of maintaining “clean” cells. Autophagy 1:3 (2005), 131–140.
9. [9] Hochfeld, W.E., Lee, S., Rubinsztein, D.C., Therapeutic induction of autophagy to modulate neurodegenerative disease progression. Acta Pharmacol. Sin. 34:5 (2013), 600–604.
10. [10] Stallone, G., Infante, B., Grandaliano, G., Gesualdo, L., Management of side effects of sirolimus therapy. Transplantation 87:8 Suppl (2009), S23–S26.
11. [11] Lan, D.M., Liu, F.T., Zhao, J., Chen, Y., Wu, J.J., Ding, Z.T., Yue, Z.Y., Ren, H.M., Jiang, Y.P., Wang, J., Effect of trehalose on PC12 cells overexpressing wild-type or A53T mutant alpha-synuclein. Neurochem. Res. 37:9 (2012), 2025–2032.
12. [12] Dehay, B., Bove, J., Rodriguez-Muela, N., Perier, C., Recasens, A., Boya, P., Vila, M., Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30:37 (2010), 12535–12544.
13. [13] Settembre, C., Di Malta, C., Polito, V.A., Garcia Arencibia, M., Vetrini, F., Erdin, S., Erdin, S.U., Huynh, T., Medina, D., Colella, P., et al. TFEB links autophagy to lysosomal biogenesis. Science 332:6036 (2011), 1429–1433.
14. [14] Sardiello, M., Palmieri, M., di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R.S., et al. A gene network regulating lysosomal biogenesis and function. Science 325:5939 (2009), 473–477.
15. [15] Sacktor, B., Trehalase and the transport of glucose in the mammalian kidney and intestine. Proc. Natl. Acad. Sci. USA 60:3 (1968), 1007–1014.
16. [16] Richards, A.B., Krakowka, S., Dexter, L.B., Schmid, H., Wolterbeek, A.P., Waalkens-Berendsen, D.H., Shigoyuki, A., Kurimoto, M., Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies. Food Chem. Toxicol.: Int. J. Publ. Br. Ind. Biol. Res. Assoc. 40:7 (2002), 871–898.
17. [17] Rodriguez-Navarro, J.A., Rodriguez, L., Casarejos, M.J., Solano, R.M., Gomez, A., Perucho, J., Cuervo, A.M., Garcia de Yebenes, J., Mena, M.A., Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiol. Dis. 39:3 (2010), 423–438.
18. [18] Castillo, K., Nassif, M., Valenzuela, V., Rojas, F., Matus, S., Mercado, G., Court, F.A., van Zundert, B., Hetz, C., Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy 9:9 (2013), 1308–1320.
19. [19] Tanaka, M., Machida, Y., Niu, S., Ikeda, T., Jana, N.R., Doi, H., Kurosawa, M., Nekooki, M., Nukina, N., Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10:2 (2004), 148–154.
20. [20] Liu, R., Barkhordarian, H., Emadi, S., Park, C.B., Sierks, M.R., Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol. Dis. 20:1 (2005), 74–81.
21. [21] Qiao, L., Hamamichi, S., Caldwell, K.A., Caldwell, G.A., Yacoubian, T.A., Wilson, S., Xie, Z.L., Speake, L.D., Parks, R., Crabtree, D., et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain, 1, 2008, 17.
22. [22] Shacka, J.J., Klocke, B.J., Young, C., Shibata, M., Olney, J.W., Uchiyama, Y., Saftig, P., Roth, K.A., Cathepsin D deficiency induces persistent neurodegeneration in the absence of Bax-dependent apoptosis. J. Neurosci. 27:8 (2007), 2081–2090.
23. [23] Walls, K.C., Klocke, B.J., Saftig, P., Shibata, M., Uchiyama, Y., Roth, K.A., Shacka, J.J., Altered regulation of phosphatidylinositol 3-kinase signaling in cathepsin D-deficient brain. Autophagy 3:3 (2007), 222–229.
24. [24] Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:1 (2000), 239–252.
25. [25] Volpicelli-Daley, L.A., Luk, K.C., Lee, V.M., Addition of exogenous alpha-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous alpha-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9:9 (2014), 2135–2146.
26. [26] Tanik, S.A., Schultheiss, C.E., Volpicelli-Daley, L.A., Brunden, K.R., Lee, V.M., Lewy body-like alpha-synuclein aggregates resist degradation and impair macroautophagy. J. Biol. Chem. 288:21 (2013), 15194–15210.
27. [27] Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24:2 (2003), 197–211.
28. [28] Sarkar, S., Davies, J.E., Huang, Z., Tunnacliffe, A., Rubinsztein, D.C., Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 282:8 (2007), 5641–5652.
29. [29] Kruger, U., Wang, Y., Kumar, S., Mandelkow, E.M., Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol. Aging 33:10 (2012), 2291–2305.
30. [30] Davies, J.E., Sarkar, S., Rubinsztein, D.C., Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum. Mol. Genet. 15:1 (2006), 23–31.
31. [31] Yu, W.B., Jiang, T., Lan, D.M., Lu, J.H., Yue, Z.Y., Wang, J., Zhou, P., Trehalose inhibits fibrillation of A53T mutant alpha-synuclein and disaggregates existing fibrils. Arch. Biochem. Biophys. 523:2 (2012), 144–150.
32. [32] Tapia, H., Koshland, D.E., Trehalose is a versatile and long-lived chaperone for desiccation tolerance. Curr. Biol.: Cb. 24:23 (2014), 2758–2766.
33. [33] Viner, R.I., Clegg, J.S., Influence of trehalose on the molecular chaperone activity of p26, a small heat shock/alpha-crystallin protein. Cell Stress Chaperones 6:2 (2001), 126–135.
34. [34] He, Q., Koprich, J.B., Wang, Y., Yu, W.B., Xiao, B.G., Brotchie, J.M., Wang, J., Treatment with Trehalose prevents behavioral and neurochemical deficits produced in an AAV alpha-synuclein rat model of Parkinson's disease. Mol. Neurobiol. 53:4 (2016), 2258–2268.